https://www.live-feeds.com/feed/people-with-type-2-diabetes-lost-up-to-60-pounds-on-lilly-s-latest-weight-loss-drugContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/people-with-type-2-diabetes-lost-up-to-60-pounds-on-lilly-s-latest-weight-loss-drughttps://www.live-feeds.com/feed/people-with-type-2-diabetes-lost-up-to-60-pounds-on-lilly-s-latest-weight-loss-drug#u94335Fri, 02 Oct 2026 09:21:00 +0000Eli Lilly reports that participants with type 2 diabetes lost up to 60 pounds in a trial of its experimental weight-loss drug, retatrutide. The triple agonist compound delivered significant weight reduction and A1C reduction in patients with obesity and type 2 diabetes. Clinical testing recorded weight loss percentages reaching up to 21 percent and 25 percent in trial settings. Observers describe the experimental treatment as a high-water mark and a powerful obesity drug option for addressing metabolic conditions.Why it mattersPharmaceutical companies continue to advance next-generation therap